Article
Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial).
PloS one - 1 Jan 2023
Awasthi Ashish, Katiyar Harshita, Rungta Sumit, Deep Amar, Kumar Vinod, Shalimar, Kumar Ajay, Tiwari Prachi, Goel Amit
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma. Globally, nearly 71 million people have chronic HCV infection, and approximately 399,000 dies annually. In patients without cirrhosis, HCV infection is treated with 12 weeks of sofosbuvir/velpatasvir combination. Results from available small, single-centre observational studies suggest that the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.